EP0666745A4 - Diagnosis and therapy for parkinson's disease. - Google Patents

Diagnosis and therapy for parkinson's disease.

Info

Publication number
EP0666745A4
EP0666745A4 EP92918207A EP92918207A EP0666745A4 EP 0666745 A4 EP0666745 A4 EP 0666745A4 EP 92918207 A EP92918207 A EP 92918207A EP 92918207 A EP92918207 A EP 92918207A EP 0666745 A4 EP0666745 A4 EP 0666745A4
Authority
EP
European Patent Office
Prior art keywords
parkinson
diagnosis
therapy
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92918207A
Other languages
German (de)
French (fr)
Other versions
EP0666745A1 (en
Inventor
Xandra O Breakefield
Gokhan S Hotamisligil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP0666745A1 publication Critical patent/EP0666745A1/en
Publication of EP0666745A4 publication Critical patent/EP0666745A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y104/00Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03004Monoamine oxidase (1.4.3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP92918207A 1991-09-20 1992-08-17 Diagnosis and therapy for parkinson's disease. Withdrawn EP0666745A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76230291A 1991-09-20 1991-09-20
US762302 1991-09-20
PCT/US1992/006746 WO1993005783A1 (en) 1991-09-20 1992-08-17 Diagnosis and therapy for parkinson's disease

Publications (2)

Publication Number Publication Date
EP0666745A1 EP0666745A1 (en) 1995-08-16
EP0666745A4 true EP0666745A4 (en) 1995-10-25

Family

ID=25064666

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92918207A Withdrawn EP0666745A4 (en) 1991-09-20 1992-08-17 Diagnosis and therapy for parkinson's disease.

Country Status (5)

Country Link
EP (1) EP0666745A4 (en)
JP (1) JPH07501518A (en)
AU (1) AU2492192A (en)
CA (1) CA2116130A1 (en)
WO (1) WO1993005783A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783680A (en) * 1993-10-06 1998-07-21 The General Hospital Corporation Genetic diagnosis and treatment for impulsive aggression
AU2001284680A1 (en) * 2000-07-28 2002-02-13 Genaissance Pharmaceuticals, Inc. Haplotypes of the alas2 gene
WO2002012561A2 (en) * 2000-08-03 2002-02-14 Genaissance Pharmaceuticals, Inc. Haplotypes of the or1g1 gene
WO2002012342A2 (en) * 2000-08-04 2002-02-14 Genaissance Pharmaceuticals, Inc. Haplotypes of the edg4 gene
AU2001294513A1 (en) * 2000-08-04 2002-02-18 Genaissance Pharmaceuticals, Inc. Haplotypes of the ntf3 gene
WO2002012498A2 (en) * 2000-08-04 2002-02-14 Genaissance Pharmaceuticals, Inc. Haplotypes of the isl1 gene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000195A1 (en) * 1988-06-30 1990-01-11 Xandra Breakefield Dna encoding human monoamine oxidase type a
WO1991018005A1 (en) * 1990-05-14 1991-11-28 Duke University Cloned genes encoding the d1 dopamine receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000195A1 (en) * 1988-06-30 1990-01-11 Xandra Breakefield Dna encoding human monoamine oxidase type a
WO1991018005A1 (en) * 1990-05-14 1991-11-28 Duke University Cloned genes encoding the d1 dopamine receptor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 5091, Derwent World Patents Index; AN 91-369177 *
G.C.M. BLACK ET AL.: "Dinucleotide repeat polymorphism at the MAOA locus", NUCLEIC ACIDS RESEARCH, vol. 19, no. 3, 11 February 1991 (1991-02-11), IRL PRESS LIMITED,OXFORD,ENGLAND, pages 689 *
G.S. HOTAMISLIGIL AND X.O. BREAKEFIELD: "Human monoamine oxidase A gene determines level of enzyme activity", AM.J. HUMAN. GENET., vol. 49, no. 2, AM.SOC.HUM.GENET.,CHICAGO,US, pages 383 - 392 *
G.S. HOTAMITLISGIL ET AL.: "Allelic variation in MAO genes mark activity states and may predict vulnerability to Parkinson disease", AM.J. HUMAN. GENET. SUPPLEMENT, vol. 49, no. 4, AM.SOC.HUM.GENET.,CHICAGO,US, pages 407 *
See also references of WO9305783A1 *
Z.-Y. CHEN ET AL.: "Structure of the human gene for monoamine oxidase type A", NUCLEIC ACIDS RESEARCH, vol. 19, no. 16, 25 August 1991 (1991-08-25), IRL PRESS LIMITED,OXFORD,ENGLAND, pages 4537 - 4541 *

Also Published As

Publication number Publication date
CA2116130A1 (en) 1993-04-01
JPH07501518A (en) 1995-02-16
AU2492192A (en) 1993-04-27
EP0666745A1 (en) 1995-08-16
WO1993005783A1 (en) 1993-04-01

Similar Documents

Publication Publication Date Title
Chaudhury Herbal medicine for human health
EP0331620A3 (en) Agent for the treatment of parkinson's disease
OA09736A (en) "Human interleukin-3 and muteins thereof".
IL119417A0 (en) Drug for Parkinson's disease
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
EP0666745A4 (en) Diagnosis and therapy for parkinson's disease.
ZA924128B (en) New combination preparations for treatment of Parkinson's disease.
EP0370115A4 (en) Catheter for diagnosis and therapy
DE59003456D1 (en) Driver's bed couch protection against falling out.
GB2239391B (en) Angler's seat or bedchair
AU2990692A (en) Diagnostic method for pompe's disease
EP0587806A4 (en) Therapeutic and diagnostic methods based on neurotrophin-4 expression.
AU8195091A (en) Ropinirole and domperidone for use in the manufacture of a medicament for the treatment of parkinson's disease
GB9323826D0 (en) Diagnosis of alzheimer's disease
Davidson Flann O'Brien's At Swim-Two-Birds and the trial of representation
GB9106247D0 (en) Human disease diagnosis
Harb Human Capital: An Overview
GB9025113D0 (en) Crohn's disease drug
GB9006464D0 (en) Human disease diagnosis
Houghton A transpersonal study of dreamwork with a cancer patient
GB9215063D0 (en) Crohn's disease drug
GB9024632D0 (en) Therapy for alzheimer's disease
GB8825491D0 (en) Therapy for alzheimer's disease
AU6955294A (en) Agents for the prevention and treatment of parkinson's disease
GB8925512D0 (en) Therapy for alzheimer's disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940414

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/53

A4 Supplementary search report drawn up and despatched

Effective date: 19950912

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960217